Incidence and Risk Factors for Post-Intravitreal Injection Endophthalmitis in a Modified Operating Room Setting

References

• Diabetic Retinopathy Clinical Research N; Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–1203. doi:10.1056/NEJMoa1414264.
   PubMed Web of Science ®Google Scholar
• Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57–65 e5. doi:10.1016/j.ophtha.2008.10.018.
   PubMed Web of Science ®Google Scholar
• Heier JS, Clark WL, Boyer DS, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology. 2014;121(7):1414–20 e1. doi:10.1016/j.ophtha.2014.01.027.
   PubMed Web of Science ®Google Scholar
• Casparis H, Wolfensberger TJ, Becker M, et al. Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study. Retina. 2014;34(1):12–17. doi:10.1097/IAE.0b013e31829f74b0.
   PubMed Web of Science ®Google Scholar
• Mason JO, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina. 2008;28(4):564–7. doi:10.1097/IAE.0b013e3181633fee.
   Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481.
   PubMed Web of Science ®Google Scholar
• Scott IU, Flynn HW Jr. Reducing the risk of endophthalmitis following intravitreal injections. Retina. 2007;27(1):10–12. doi:10.1097/IAE.0b013e3180307271.
   PubMed Web of Science ®Google Scholar
• Ta CN. Minimizing the risk of endophthalmitis following intravitreous injections. Retina. 2004;24:699–705.
   PubMed Web of Science ®Google Scholar
• Storey P, Dollin M, Pitcher J, et al.; Post-Injection Endophthalmitis Study Team. The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection. Ophthalmology. 2014;121(1):283–289. doi:10.1016/j.ophtha.2013.08.037.
   PubMed Web of Science ®Google Scholar
• Cheung CS, Wong AW, Lui A, Kertes PJ, Devenyi RG, Lam WC. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology. 2012;119(8):1609–1614. doi:10.1016/j.ophtha.2012.02.014.
   PubMed Web of Science ®Google Scholar
• Green-Simms AE, Ekdawi NS, Bakri SJ. Survey of intravitreal injection techniques among retinal specialists in the United States. Am J Ophthalmol. 2011;151(2):329–332. doi:10.1016/j.ajo.2010.08.039.
   PubMed Web of Science ®Google Scholar
• Michels S, Becker M, Wachtlin J, Binder S. The intravitreal injection: variations in regulations, cost and reimbursement in Europe. Spektrum der Augenheilkunde. 2012;26(1):2–6. doi:10.1007/s00717-012-0072-2.
   Web of Science ®Google Scholar
• Brynskov T, Kemp H, Sorensen TL. No cases of endophthalmitis after 20,293 intravitreal injections in an operating room setting. Retina. 2014;34(5):951–957. doi:10.1097/IAE.0000000000000071.
   PubMed Web of Science ®Google Scholar
• Nentwich MM, Yactayo-Miranda Y, Schwarzbach F, Wolf A, Kampik A, Mino de Kaspar H. Endophthalmitis after intravitreal injection: decreasing incidence and clinical outcome-8-year results from a tertiary ophthalmic referral center. Retina. 2014;34(5):943–950. doi:10.1097/IAE.0000000000000011.
   PubMed Web of Science ®Google Scholar
• Abell RG, Kerr NM, Allen P, Vote BJ. Intravitreal injections: is there benefit for a theatre setting? Br J Ophthalmol. 2012;96(12):1474–1478. doi:10.1136/bjophthalmol-2012-302030.
   PubMed Web of Science ®Google Scholar
• Sigford DK, Reddy S, Mollineaux C, Schaal S. Global reported endophthalmitis risk following intravitreal injections of anti-VEGF: a literature review and analysis. Clin Ophthalmol. 2015;9:773–781. doi:10.2147/OPTH.S77067.
   PubMed Web of Science ®Google Scholar
• Falavarjani KG, Modarres M, Hashemi M, et al. Incidence of acute endophthalmitis after intravitreal bevacizumab injection in a single clinicalcenter. Retina. 2013 May;33(5):971–974. doi:10.1097/IAE.0b013e31826f0675.
   PubMed Web of Science ®Google Scholar
• Falavarjani KG, Aghamirsalim M, Modarres M, et al. Endophthalmitis after resident-performed intravitreal bevacizumab injection. Can J Ophthalmol. 2015 Feb;50(1):33–36. doi:10.1016/j.jcjo.2014.09.005.
   PubMed Web of Science ®Google Scholar
• Goldberg RA, Flynn HW Jr., Isom RF, Miller D, Gonzalez S. An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol. 2012;153(2):204–8 e1. doi:10.1016/j.ajo.2011.11.035.
   PubMed Web of Science ®Google Scholar
• Inoue M, Kobayakawa S, Sotozono C, et al. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor. Ophthalmologica. 2011;226(3):145–150. doi:10.1159/000329863.
   PubMed Web of Science ®Google Scholar
• Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye (Lond). 2009;23(12):2187–2193. doi:10.1038/eye.2009.7.
   PubMed Web of Science ®Google Scholar
• Sheyman AT, Cohen BZ, Friedman AH, Ackert JM. An outbreak of fungal endophthalmitis after intravitreal injection of compounded combined bevacizumab and triamcinolone. JAMA Ophthalmol. 2013;131(7):864–869. doi:10.1001/jamaophthalmol.2013.88.
   PubMed Web of Science ®Google Scholar
• Wani VB, Al-Kandari J, Sabti K, et al. Incidence of endophthalmitis after intravitreal bevacizumab using aliquots prepared on-site in 2 operating rooms in Kuwait. Middle East Afr J Ophthalmol. 2016;23(1):64–70. doi:10.4103/0974-9233.171784.
   PubMed Web of Science ®Google Scholar
• Merani R, Hunyor AP. Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review. Int J Retina Vitreous. 2015;1:9. doi:10.1186/s40942-015-0010-y.
   PubMedGoogle Scholar
• Diabetic Retinopathy Clinical Research N; Scott IU, Edwards AR, Beck RW, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114(10):1860–1867. doi:10.1016/j.ophtha.2007.05.062.
   PubMed Web of Science ®Google Scholar
• McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011;31(4):654–661. doi:10.1097/IAE.0b013e31820a67e4.
   PubMed Web of Science ®Google Scholar
• Lima LH, Zweifel SA, Engelbert M, et al. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy. Retina. 2009;29(9):1213–1217. doi:10.1097/IAE.0b013e3181b32d27.
   PubMed Web of Science ®Google Scholar
• Chen E, Ho AC, Garg SJ, Brown GC, Kaiser RS. Streptococcus mitis endophthalmitis presenting as frosted branch angiitis after intravitreal pegaptanib sodium injection. Ophthalmic Surg Lasers Imaging. 2009;40:192–194.
   PubMedGoogle Scholar
• Storey P, Dollin M, Rayess N, et al.; Post-Injection Endophthalmitis Study Team. The effect of prophylactic topical antibiotics on bacterial resistance patterns in endophthalmitis following intravitreal injection. Graefes Arch Clin Exp Ophthalmol. Feb 2016;254(2):235–242. doi:10.1007/s00417-015-3035-x.
   PubMed Web of Science ®Google Scholar
• Roth DB, Realini T, Feuer WJ, et al. Short-term complications of intravitreal injection of triamcinolone acetonide. Retina. 2008;28(1):66–70. doi:10.1097/IAE.0b013e3181593e38.
   PubMed Web of Science ®Google Scholar
• Dodwell DG, Krimmel DA, de Fiebre CM. Sterile endophthalmitis rates and particle size analyses of different formulations of triamcinolone acetonide. Clin Ophthalmol. 2015;9:1033–1040. doi:10.2147/OPTH.S82562.
   PubMed Web of Science ®Google Scholar